Revvity (NYSE:RVTY) Stock Gets Price Target Boost from JPMorgan Chase & Co.

Revvity (NYSE:RVTY) had its price target hoisted by research analysts at JPMorgan Chase & Co. from $155.00 to $160.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential downside of 1.51% from the company’s previous close.

A number of other equities analysts have also recently commented on RVTY. Bank of America reissued a “neutral” rating on shares of Revvity in a report on Wednesday. Weiss Ratings raised Revvity from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Cfra upgraded Revvity from a “hold” rating to a “buy” rating in a research report on Wednesday. William Blair initiated coverage on Revvity in a research note on Monday, October 5th. They issued an “outperform” rating for the company. Finally, Evercore reissued an “outperform” rating on shares of Revvity in a research note on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $133.86.

Revvity Price Performance

Shares of RVTY stock traded down $1.02 on Wednesday, reaching $162.46. 1,684,210 shares of the company were exchanged, compared to its average volume of 1,536,434. Revvity has a 1 year low of $81.22 and a 1 year high of $171.74. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The business has a 50-day moving average price of $145.89 and a 200 day moving average price of $112.62. The company has a market cap of $18.13 billion, a price-to-earnings ratio of 77.20, a P/E/G ratio of 2.76 and a beta of 1.08.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.08. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm had revenue of $728.90 million for the quarter, compared to analyst estimates of $694.73 million. During the same period last year, the company posted $1.18 EPS. Revvity’s quarterly revenue was up 4.3% compared to the same quarter last year. Equities research analysts forecast that Revvity will post 5.36 earnings per share for the current fiscal year.

Insider Activity at Revvity

In related news, insider Maxwell Krakowiak sold 1,631 shares of the firm’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the sale, the insider directly owned 14,781 shares in the company, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tajinder S. Vohra sold 7,330 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the sale, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. This represents a 52.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 9,045 shares of company stock worth $1,281,439. Insiders own 0.85% of the company’s stock.

Institutional Trading of Revvity

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jupiter Topco LLC acquired a new position in shares of Revvity in the 2nd quarter worth approximately $961,017,000. BlackRock Inc. purchased a new position in Revvity in the second quarter valued at $852,070,000. Wellington Management Group LLP grew its position in shares of Revvity by 10,653.8% during the second quarter. Wellington Management Group LLP now owns 865,575 shares of the company’s stock worth $96,304,000 after buying an additional 857,526 shares in the last quarter. Primecap Management Co. CA acquired a new position in Revvity during the 2nd quarter worth approximately $94,921,000. Finally, Bank of America Corp DE purchased a new position in Revvity in the second quarter valued at $87,116,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported Q3 adjusted EPS of $1.38, above the roughly $1.30 consensus, and revenue of $728.9 million versus estimates of about $694.7 million. Revenue grew 4.3% year over year, with Life Sciences strength and margin expansion contributing to the beat. The company also raised its 2026 outlook. Q3 earnings beat and outlook
• Positive Sentiment: CFRA upgraded RVTY from Hold to Buy, adding a favorable analyst view after the results. CFRA upgrade
• Neutral Sentiment: Royal Bank of Canada raised its price target from $135 to $172 but retained a Sector Perform rating; the new target implied about 6.3% upside at the cited share price. RBC price target
• Neutral Sentiment: Some coverage questioned whether the stock is now expensive after its earnings-driven run. That concern may limit further gains, particularly given the high valuation noted in the provided market data. Dividend and valuation discussion

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.